Zahn Julia, Wimmer Stefan, Rödle Wolfgang, Toni Irmgard, Sedlmayr Brita, Prokosch Hans-Ulrich, Rascher Wolfgang, Neubert Antje
Department of Paediatrics and Adolescent Medicine, Faculty of Medicine, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Department of Pharmacy, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
Pharmacy (Basel). 2021 Jan 5;9(1):8. doi: 10.3390/pharmacy9010008.
Off-label use is frequent in paediatrics but that does not necessarily mean that the risk-benefit ratio is negative. Nevertheless, evidence-based data is essential for safe drug therapy. In Germany, there is no publicly available compendium providing transparent, evidence-based information for paediatric pharmacotherapy to date. This work describes the development of a web-based paediatric drug information system (PDIS) for Germany and its evaluation by health care professionals (HCP). Since 2012, a PDIS is being developed by the authors and is supported by the Federal Ministry of Health since 2016. Dosing recommendations were established based on systematic literature reviews and subsequent evaluation by clinical experts. The prototype was evaluated by HCP. Based on the results, the further development was concluded. 92% of HCP believed that the PDIS could improve the quality of prescribing, as currently available information is deficient. Besides the license and formulations, dosing recommendations were the most relevant modules. A dosage calculator was the most wanted improvement. To facilitate sustainability of future development, a collaboration with the Dutch Kinderformularium was established. As of 2021, the database will be available to German HCP. The fundamentals for a German PDIS were established, and vital steps were taken towards successful continuation.
在儿科中,药物的非标签使用很常见,但这并不一定意味着风险效益比为负。然而,循证数据对于安全的药物治疗至关重要。在德国,至今尚无公开可用的纲要为儿科药物治疗提供透明的、基于证据的信息。这项工作描述了德国一个基于网络的儿科药物信息系统(PDIS)的开发及其由医疗保健专业人员(HCP)进行的评估。自2012年以来,作者们一直在开发PDIS,自2016年起得到联邦卫生部的支持。剂量推荐是基于系统的文献综述以及临床专家随后的评估而制定的。该原型由HCP进行评估。基于评估结果,完成了进一步的开发。92%的HCP认为PDIS可以提高处方质量,因为目前可用的信息不足。除了药品许可和剂型外,剂量推荐是最相关的模块。剂量计算器是最需要改进的方面。为了促进未来发展的可持续性,与荷兰儿童处方集建立了合作关系。截至2021年,该数据库将可供德国的HCP使用。德国PDIS的基础已经确立,并朝着成功延续迈出了关键步骤。